FibroBiologics Inc. (FBLG) – What Are Researchers Saying About This Stock?

FibroBiologics Inc. (NASDAQ:FBLG) has earned a consensus rating of “Reduce” from the five ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $73.00.

FBLG has been the topic of several analyst reports. Deutsche Bank lowered shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a research report on Tuesday, August 4th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. Finally, Wall Street Zen upgraded shares of FibroBiologics to a “hold” rating in a report on Saturday, October 10th.

Institutional Trading of FibroBiologics

A hedge fund recently bought a new stake in FibroBiologics stock. IFP Advisors Inc bought a new stake in FibroBiologics Inc. (NASDAQ:FBLG) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 27,000 shares of the company’s stock, valued at approximately $35,000. IFP Advisors Inc owned 0.41% of FibroBiologics at the end of the most recent quarter.

FibroBiologics Price Performance

NASDAQ:FBLG opened at $1.00 on Thursday. The company’s 50-day moving average is $1.21 and its two-hundred day moving average is $2.20. FibroBiologics has a 1-year low of $0.62 and a 1-year high of $9.60. The firm has a market capitalization of $6.63 million, a price-to-earnings ratio of -0.19 and a beta of 1.81.

FibroBiologics Company Profile

FibroBiologics, Inc. is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research focuses on fibroblasts, connective-tissue cells that may support tissue repair and influence immune-system activity, as well as biologically active materials derived from these cells. The company is developing a platform that includes fibroblast-based cell therapies and fibroblast-derived extracellular vesicles. These potential treatments are intended to address conditions involving chronic inflammation, immune dysfunction, and tissue damage.